State-of-the-Art Obesity Management in the Primary Care Setting
June 30, 2023
June 15, 2024
This activity is provided by the University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from Lilly.
- Physicians — maximum of 3.0 AMA PRA Category 1 Credit(s)™
This activity is intended for the multidisciplinary clinical team managing patients with obesity in the primary care practice setting.
Access our robust online slide library covering the management of obesity in the primary care setting. Expert faculty in weight management developed content related to epidemiology, pathophysiology, and complications of obesity; screening and diagnosis; patient counseling; case studies; nonpharmacologic therapies; and pharmacologic therapies. Choose your topic interests and customize your own slide deck to broaden your knowledge and improve the care and outcomes of patients with obesity.
Obesity is not a lifestyle choice or a failure of willpower. It is a chronic disease, and it affects more than 40% of adults in the US. Do you wonder…
- How to talk to patients about their weight?
- When and how to incorporate pharmacologic therapies within individualized management plans for patients with obesity?
- Why patients with obesity often struggle with maintaining weight loss?
Customize your learning experience now and find the answers to these questions and more!
Upon completion of this activity, learners will be able to:
- Describe the current guideline recommended strategies for screening for obesity in clinical practice and methods to improve diagnosis of obesity as a treatable chronic disease
- Analyze recent efficacy and safety outcomes of clinical trials with anti-obesity medications (AOMs)
- Illustrate methods to engage appropriate patients in discussion on available lifestyle modifications and weight loss strategies, which may include the use of AOMs
Caroline Apovian, MD
Professor of Medicine
Harvard Medical School
Co-Director, Center for Weight Management and Wellness
Brigham and Women’s Hospital
Silvana Pannain, MD
Obesity Medicine Director for the Center for Weight and Metabolic Health
University of Chicago
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 3.0 maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept maximum of 3.0 AMA PRA Category 1 Credit(s)™ through their reciprocity agreements.
Disclosures of Conflicts of Interest
The University of Chicago Pritzker School of Medicine requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
- Caroline Apovian, MD (Chair)
Advisory Board: Abbott Nutrition, Allergan Inc., Altimmune Inc., Cowen and Company LLC,
Curavit Clinical Research, EnteroMedics, Gelesis, Srl., Jazz Pharmaceuticals Inc., L-Nutra, Inc.,
NeuroBo Pharmaceuticals Inc., Novo Nordisk Inc., Pain Script Corporation, Real Appeal, Rhythm
Pharmaceuticals, Roman Health Ventures Inc., Scientific Intake Ltd. Co., Tivity Health Inc., Xeno
Biosciences, Zafgen Inc.
Sources of Funding for Research: Novo Nordisk, GI Dynamics Inc.
- Silvana Pannain, MD (Chair)
Advisory Board: Lilly, Novo Nordisk
Contract Speaker: Novo Nordisk
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: tirzepatide, cagrilinitide, mazdutide (IBI362), sibutramine, ecnoglutide (XW003), danuglipron, LY3502970, ZP8396, CT-388, AMG-133, pemvidutide, BI 456906, NN 9277, and retatrutide are investigational therapies and are not approved by the FDA for the treatment of obesity. Topiramate is not approved by the FDA as a monotherapy for the treatment of obesity.
Instructions for Participation and Credit
Certificates awarding maximum of 3.0 AMA PRA Category 1 Credit(s)™ or certificates documenting participation will be issued immediately to participants when an individual completes the posttest and evaluation.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
For CME questions, please contact Laurie Novoryta at Lnovoryta@achlcme.org.